Accessibility Menu
CanSino Biologics logo

CanSino Biologics(OTC) CASBF

Market Cap$776.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-58%
5 Year-92%
1 Year-36%
1 Month+10%
$3.15
+0.00%
+0.00Today
CanSino Biologics last closing stock price
MetricPriceDate
Last closeUSD 3.152026-07-23
CanSino Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+20.96%USD 2.602026-07-09
1 month+9.97%USD 2.862026-06-18
3 month-18.52%USD 3.862026-04-15
Year to date-33.72%USD 4.752025-12-31
1 year-35.82%USD 4.902025-07-23
3 year-6.13%USD 3.352023-07-24
5 year-91.84%USD 38.552021-07-23
Since inception-58.07%USD 7.502020-01-02

CanSino Biologics Financials at a Glance

Market Cap

$776.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.11B

Net Income (TTM)

-CN¥836.08K

EPS (TTM)

-$0.00

P/E Ratio

-2419.23

Dividend

$0.00

Beta (Volatility)

-0.15 (Low)

Price

$3.15

Volume

2

Open

$3.15

Previous Close

$3.15

Daily Range

$3.15 - $3.15

52-Week Range

$2.60 - $6.99

Estimated Earnings Date

Aug 29, 2026

CASBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CanSino Biologics

CanSino Biologics Inc. is a leading biotechnology company focused on the development, manufacturing, and commercialization of vaccines in China. The company is known for its innovative vaccine solutions, including those for COVID-19 and other infectious diseases.

Products and Services
  • Convidecia, a COVID-19 vaccine with inhalation delivery
  • Ad5-EBOV, an Ebola virus vaccine
  • DTcP vaccines for infants and adolescents targeting pertussis
Growth Outlook
  • Strong pipeline with multiple vaccines in various clinical trial phases
  • Expansion into international markets for vaccine distribution
  • Increased R&D investment to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of 188 million CNY, showing growth potential
  • Cash and short-term investments totaling 2.07 billion CNY
  • Current ratio of 4.11, indicating strong liquidity position
CanSino Biologics Inc. has established itself as a key player in the vaccine market, particularly with its COVID-19 vaccine, Convidecia. The company is actively expanding its product portfolio, which includes vaccines for various infectious diseases, thereby positioning itself for future growth. The strong financial position, highlighted by significant cash reserves and a favorable current ratio, provides a solid foundation for ongoing research and development efforts. With a focus on innovation and market expansion, CanSino Biologics Inc. presents an intriguing opportunity for investors interested in the biotechnology sector.
AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,134

CEO

Xue Feng Yu, PhD

Website

www.cansinotech.com

Headquarters

Tianjin, TI 300457, CN

CASBF Financials

Key Financial Metrics (TTM)

Gross Margin

75.00%

Operating Margin

-0.16%

Net Income Margin

-0.09%

Return on Equity

-0.02%

Return on Capital

-1.81%

Return on Assets

-0.01%

Earnings Yield

-0.04%

Dividend Yield

0.00%

Payout Ratio

-12.32%

Stock Overview

Market Cap

$776.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

247.04M

Volume

2

Avg. Volume

95.333

Financials (TTM)

Gross Profit

CN¥826.21M

Operating Income

-CN¥71.73M

EBITDA

CN¥29.23M

Operating Cash Flow

CN¥71.33M

Capital Expenditure

-CN¥208.80M

Free Cash Flow

-CN¥137.38M

Cash & ST Invst.

CN¥2.07B

Total Debt

CN¥1.16B

CanSino Biologics Performance Analysis

CanSino Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 153,644,038-77.0%
20232023-12-31CNY 49,276,079-67.9%
20242024-12-31CNY 116,180,186135.8%
20252025-12-31CNY 148,558,78927.9%
CanSino Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3078.7%
Q32025-09-3026.5%
Q42025-12-3119.3%
Q12026-03-31-49.0%
CanSino Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.55N/A
20232023-12-31CNY -0.8555.0%
20242024-12-31CNY -0.21-74.9%
20252025-12-31CNY 0.02N/A
CanSino Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3087.4%
Q32025-09-301846.0%
Q42025-12-31-53.6%
Q12026-03-31-413.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CN¥188.46M

+37.4%

Gross Profit

CN¥152.55M

+34.5%

Gross Margin

80.94%

N/A

Market Cap

$776.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$685.14K

N/A

Employees

1,134

N/A

Net Income

-CN¥40.04M

-246.8%

EBITDA

-CN¥41.75M

-249.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CN¥2.07B

-32.9%

Total Debt

CN¥1.16B

-41.7%

Accounts Receivable

CN¥817.60M

+22.8%

Inventory

CN¥399.53M

+23.9%

Long Term Debt

CN¥949.01M

-15.7%

Short Term Debt

CN¥208.25M

-75.7%

Return on Assets

-0.01%

N/A

Return on Invested Capital

-0.03%

N/A

Free Cash Flow

-CN¥88.49M

-9.0%

Operating Cash Flow

-CN¥57.71M

-318.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
CURLFCuraleaf Holdings, Inc.
$9.28+0.65%
LBTSFAlmirall, S.A.
$15.35-0.78%
APNHYAspen Pharmacare Holdings Limited
$9.41+5.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About CASBF

What is the current price of CanSino Biologics?

CanSino Biologics is trading at $3.15 per share.

What is the 52-week range for CanSino Biologics?

Over the past 52 weeks, CanSino Biologics has traded between $2.60 and $6.99.

How much debt does CanSino Biologics have?

As of the most recent reporting period, CanSino Biologics reported total debt of CN¥168.17M.

How much cash does CanSino Biologics have on hand?

CanSino Biologics reported CN¥162.25M in cash and cash equivalents in its most recent financial results.

What is CanSino Biologics’s dividend yield?

CanSino Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services